Cancer has been a major health problem over the years, with many lives getting cut short and no known definite medical cure for it. Medical, health and wellness companies have been carrying out research over the years with many theories and postulations all over the place, but nothing compelling has been established thus far. However, the health and wellness company, Tactical Therapeutics Inc., seems to be making headway with its drug, Carboxyamidotriazole Orotate (CTO), undergoing studies for the treatment of brain cancer.

Since it showed promising results, Carboxyamidotriazole Orotate has been administered in a Phase IB trial at Memorial Sloan-Kettering Cancer Center and now, its producer, Tactical Therapeutics Inc. is set to represent at the MedInvest Oncology Investor Conference taking place from December 14 to December 15, 2022, in New York, NY. The company, a clinical-stage biopharma, has been dedicated to improving global health and wellness and has set numerous initiatives in motion to achieve its mission. “We are honored to be selected to present at this unique event,” Rashida Karmali, Ph. D, the CEO of Tactical Therapeutics, said. “We welcome the chance to interact with many of the world’s most accomplished leaders and investors who are all dedicated to improving the health and lives of patients with glioblastoma and difficult-to-treat, resistant solid cancers,” Karmali stated.

At the core of Tactical Therapeutics Inc.’s headway in the health and wellness space is significant progress with Glioblastoma, recurrent Glioblastoma (rGBM) and newly diagnosed Glioblastoma (nGBM). Glioblastoma, the brain tumor that killed Senator Ted Kenedy, Senator John McCain and Beau Biden, has been raging and showing up in many people’s diagnoses. Mostly untreatable, many veterans of Iraq, Vietnam and Afghanistan who have been exposed to Burn Pits developed GBM, which leads to severe debilitating neurological symptoms and higher suicide rates compared to any other form of cancer. GBM has also been recorded to have an overall survival rate of between 12 to 20 months for nGBM, even after surgery, radiotherapy and adjuvant temozolomide. For rGBM, the survival period is less than ten months.

With Tactical Therapeutics Inc.’s Carboxyamidotriazole Orotate (CTO), in Phase IB, the overall survival for nGBM rose from ten to 28+ months. The oral, safe, and brain-penetrating drug showed great promise, and now, it is on course to achieving global adoption once all tests and research have been concluded. “CTO has shown highly promising results in patients with glioblastoma and other malignant gliomas, which are devastating diseases. I have no question in my mind that this drug deserves further studies to confirm efficacy, which hopefully will lead to FDA approval,” Dr. Antonio Omuro, Fellow of the American Academy of Neurology, who also oversaw the Phase IB, said.

The phase 2 randomized trial for the drug will be launched soon, and Tactical Therapeutics Inc. is sourcing for funding to make the dream possible. The goal is to make CTO a certified and approved drug for cancer treatment so the world can move forward from the fear of the deadly disease.